Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.
Multiple Myeloma
BIOLOGICAL: IM21 CAR-T cells
Incidence of adverse events (AEs), Incidence of treatment related AEs, Up to 28 days after CAR-T cell infusion|Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow ), The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR., Up to 24 weeks after CAR-T cell infusion
Objective response rate (ORR), Up to 24 weeks after CAR-T cell infusion|Overall survival (OS), Up to 24 weeks after CAR-T cell infusion|Minimal residual disease（MRD）, Up to 24 weeks after CAR-T cell infusion|Duration of Response (DOR), Up to 24 weeks after CAR-T cell infusion
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.